EirGenix Makes Progress With Trastuzumab Biosimilar
Company Plans To Submit Filings To Both FDA and EMA
Executive Summary
Taiwan’s EirGenix has made progress with its trastuzumab biosimilar for breast cancer, EG12014, announcing positive Phase III clinical results for the Herceptin equivalent.
You may also be interested in...
Deficient Aseptic Filling And Freeze Drying Hamstring Sandoz’s US Herceptin
Sandoz spoke to Generics Bulletin in the wake of confirming a recent complete response letter for its partnered biosimilar Herceptin candidate in the US.
Sandoz EMA Trastuzumab Application Follows US Filing
Sandoz and EirGenix have followed their US filing for a biosimilar rival to Herceptin with a European filing for the EG12014 trastuzumab candidate.
Sandoz Files US Trastuzumab With EirGenix
Sandoz has filed the proposed trastuzumab biosimilar developed by partner EirGenix with the US FDA. If approved, the product will have to compete in an already busy market for Herceptin biosimilars.